Open access journal of the Ferrata-Storti Foundation, a non-profit organization
Comments

Early Intensification with bendamustine supercharge plus brentuximab vedotinfollowing failure to obtain complete metabolic remission after two cycles of ABVD inpatients aged ≤60 years with classic Hodgkin lymphoma. Comment on:“Brentuximab-vedotin and bendamustine for relapsed or refractory Hodgkinlymphoma: the LYSA real-world experience”

Department of Clinical Medicine and Surgery, Hematology Unit, Federico II University Medical School, Via Sergio Pansini, 5, Naples, 80131
Department of Clinical Medicine and Surgery, Hematology Unit, Federico II University Medical School, Via Sergio Pansini, 5, Naples, 80131
Haematologica Early view Jun 18, 2026 https://doi.org/10.3324/haematol.2026.301273

Abstract

Not available.

Figures & Tables

Article Information

Early view : Comments
 
DOI
https://doi.org/10.3324/haematol.2026.301273
 
Published
2026-06-18
Published By
Ferrata Storti Foundation, Pavia, Italy
Print ISSN
0390-6078
Online ISSN
1592-8721
 
Copyright & Usage
Copyright (c) 2026 Ferrata Storti Foundation
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Article Usage

No Data Yet
No Data
PlumX
Navigate
For Authors
For Reviewers
For Advertisers
Education
Privacy
More
Copyright © 2026 by the Ferrata Storti Foundation | Web design ￫ | Development ￫
ISSN 0390-6078 print | ISSN 1592-8721 online